Results 81 to 90 of about 3,692,049 (193)
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen +14 more
wiley +1 more source
CD93—An emerging vascular target in cancer therapy
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira +3 more
wiley +1 more source
Characterisation of the role of KLF5 in normal haemopoiesis and acute myeloid leukaemia. [PDF]
Krüppel-like factor 5 (KLF5) encodes a zinc finger transcription factor involved in growth, differentiation and apoptosis of a number of different tissues, and it has previously been implicated as either a tumour suppressor or oncogene in various solid ...
Diakiw, Sonya
core
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Reid, AG +11 more
core
Monocytes Derived From Human Pluripotent Stem Cells Engineered for Detection of Pyrogens
In summary, we have developed a monocyte‐based reporter system using hESC‐Mono for interrogating the NF‐κB signalling axis, a central pathway governing pyrogenic responses. Our platform enables rapid and dose‐dependent detection of both endotoxins (LPS) and non‐endotoxins (LTA and Zymosan).
Jingjing Liu +8 more
wiley +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
Estudo da associação de genes e proteínas de resistência a múltiplos fármacos (abcb1/ABCB1, abcc1/ABCC1 e lrp/LRP) com marcadores moleculares em pacientes portadores de leucemias agudas [PDF]
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2013.Menos de 45% dos portadores de leucemias agudas (LAs) sobrevivem cinco anos após o diagnóstico. O insucesso
Moraes, Ana Carolina Rabello de
core
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley +1 more source
From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger +3 more
wiley +1 more source

